Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | ![]() Acute Myeloid Leukemia (AML) –Tumour Slide Deck 2023Mellalta Meets conducted a Competitive Landscape & Competitive Intelligence study on the G7 Acute Myeloid Leukemia market. The research aimed to analyze market dynamics, treatment trends, disruptive events, and critical opportunities
By: Mellalta Meets There were no approved treatments for decades for acute myeloid leukaemia (AML) other than chemotherapies. The past six years has witnessed the approval of eleven new therapies for AML; Rydapt / midostaurin (Novartis), Vyxeos (CPX-351) / cytarabine/daunorubicin liposomal formulation (Jazz, Nippon Shinyaku), Idhifa / enasidenib (BMS, Servier), Mylotarg / gemtuzumab ozogamicin (UCB, PDL, Pfizer), Tibsovo / ivosidenib (Servier), Venclexta / venetoclax (Roche, AbbVie), Xospata / gilteritinib (Astellas), Daurismo / glasdegib (Pfizer), Vanflyta / quizartinib (Daiichi Sankyo), Onureg (azacitidine oral) and Rezlidhia / olutasidenib (Forma Therapeutics) How are these agents faring on the market so far and will more personalised treatments follow their lead? All the drugs above form part of a rich pipeline, but which drugs stand out to key opinion leaders (KOLs)? Learn how AML's market is evolving, and how our analyst expects developers to differentiate their pipeline therapies in the Slide Deck: Acute Myeloid Leukaemia. Key coverage and questions answered…
End
|
|